Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Treasury Shares: 2022-2025

Historic Treasury Shares for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $54,665.

  • SAB Biotherapeutics' Treasury Shares rose 200.00% to $54,665 in Q3 2025 from the same period last year, while for Sep 2025 it was $54,665, marking a year-over-year increase of 200.00%. This contributed to the annual value of $54,665 for FY2024, which is 200.00% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Treasury Shares is $5.5 million, which was down 0.00% from $5.5 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Treasury Shares high stood at $546,658 for Q1 2022, and its period low was -$54,665 during Q4 2023.
  • Its 3-year average for Treasury Shares is $5.5 million, with a median of $5.5 million in 2025.
  • Per our database at Business Quant, SAB Biotherapeutics' Treasury Shares slumped by 200.00% in 2023 and then skyrocketed by 200.00% in 2024.
  • Over the past 4 years, SAB Biotherapeutics' Treasury Shares (Quarterly) stood at $5.5 million in 2022, then remained steady at $5.5 million in 2023, then remained steady at $5.5 million in 2024, then remained steady at $5.5 million in 2025.
  • Its Treasury Shares stands at $54,665 for Q3 2025, versus -$54,665 for Q2 2025 and -$54,665 for Q1 2025.